Inventor
Peter Orth
Inventor
New York, NY, US
Overview
Patents· 26 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
A61KPreparations for medical, dental or toiletry purposes23%
C07DHeterocyclic compounds20%
C07KPeptides14%
C12NMicroorganisms or enzymes9%
Y02ATechnologies for adaptation to climate change4%
C07CAcyclic or carbocyclic compounds3%
C30BSingle-crystal growth1%
PatentTitleYear
11,014,920Factor XIIa inhibitors202110,875,851Factor XIIa inhibitors20209,809,648'Engineered anti-IL-23p19 antibodies'20179,803,010'Crystalline anti-human IL-23p19 antibodies'20179,181,632'C.difficile toxin B CROP domain peptides, antibodies and complexes thereof'20158,889,683'Substituted quinoxalines as inhibitors of fatty acid binding protein'20148,815,875'Inhibitors of fatty acid binding protein (FABP)'20148,759,357'Inhibitors of fatty acid binding protein (FABP)'20148,679,472'Crystal of human interferon alpha 2B in complex with zinc'20148,513,389'Engineered anti-IL-23p19 antibodies'20138,207,219'Ion channel modulating activity I'20127,879,890'Compounds for the treatment of inflammatory disorders'20117,824,897'Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof'20107,807,160'Engineered anti-IL-23 antibodies'20107,700,753'Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof'20107,687,527'Compounds for the treatment of inflammatory disorders'20107,683,085'Compounds for the treatment of inflammatory disorders'20107,674,820'Ion channel modulating activity I'20107,652,020'Compounds for the treatment of inflammatory disorders'20107,529,628'Methods for identifying modified tumor necrosis factor-alpha converting enzyme inhibitors'20097,507,545'Ion channel modulating activity method'20097,504,424'Compounds for the treatment of inflammatory disorders'20097,488,745'Compounds for the treatment of inflammatory disorders'20097,482,370'Compounds for the treatment of inflammatory disorders'20097,285,408'Crystalline form of an n231 mutant catalytic domain of ADAM33 and methods of use thereof'20077,138,264'Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof'2006Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2006–2011Patents assigned to SCHERING CORP (13)· patent assignee history
2006–2017Based in New York, NY, US· patent location history
2009–2012Patents assigned to CARDIOME PHARMA CORP (3)· patent assignee history
2009–2012Based in Vancouver, CA· patent location history
2013–2021Patents assigned to MERCK SHARP & DOHME (10)· patent assignee history
2013–2020Patents assigned to ORTH PETER (6)· patent assignee history
2014Patents assigned to SHIPPS JR GERALD W (3)· patent assignee history
2015Based in Bronxville, NY, US· patent location history
2017Based in Kenilworth, NJ, US· patent location history
2020–2021Based in Pittstown, NJ, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SCHERING CORP | 13 | 2006–2011 |
| MERCK SHARP & DOHME | 10 | 2013–2021 |
| ORTH PETERself | 6 | 2013–2020 |
| CARDIOME PHARMA CORP | 3 | 2009–2012 |
| SHIPPS JR GERALD W | 3 | 2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| New York, New York, US | 18 | 2006–2017 |
| Vancouver, CA | 3 | 2009–2012 |
| Pittstown, New Jersey, US | 2 | 2020–2021 |
| Kenilworth, New Jersey, US | 1 | 2017 |
| Bronxville, New York, US | 1 | 2015 |